COMMUNIQUÉS West-GlobeNewswire

-
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
07/05/2025 -
PrimeBiome Reviews Consumer Reports: Critical Complaints & Customer Reviews Exposed!
07/05/2025 -
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
07/05/2025 -
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
07/05/2025 -
Dogecoin Cash, Inc. Confirms Stock Dividend Record and Payment Dates; FINRA Publication Completed
07/05/2025 -
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
07/05/2025 -
Dunham House Breaks Ground on Transformational Housing for Combat-Wounded Veterans
06/05/2025 -
WeightWatchers Takes Strategic Action to Eliminate $1.15 Billion of Debt, Strengthening Financial Position for Long-Term Growth and Profitability
06/05/2025 -
Extendicare Announces 2025 First Quarter Results
06/05/2025 -
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2025 Financial Results on May 8, 2025
06/05/2025 -
BetterLife Announces Debt Settlements
06/05/2025 -
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
06/05/2025 -
WW International, Inc. Schedules Investor Conference Call
06/05/2025 -
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
06/05/2025 -
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025
06/05/2025 -
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025
06/05/2025 -
Cellectis to Report First Quarter Financial Results on May 12, 2025
06/05/2025 -
Cellectis publiera ses résultats financiers du premier trimestre le 12 mai 2025
06/05/2025 -
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
06/05/2025
Pages